KoreaTimes - Bio

The Korea Times

The Korea Times

The Korea Times

Business

Bio

Sun, September 24, 2023 | 13:37

Samsung Biologics seeks to expand partnerships at CPhI

Samsung Biologics seeks to expand partnerships at CPhI

FRANKFURT - Samsung Biologics and other biotechnology companies in Korea will showcase their technologies and seek more business opportunities with global buyers at this year's CPhI bio pharmaceutical exhibition, according to the companies, Monday. The CPhI is an annual exhibition in the bio pharmaceutical industry held in Europe. This year's event will be held for three days...

Baek Byung-yeul | 2022-10-31 15:36

HLB Science to showcase sepsis treatment at BIO-Europe

HLB Science to showcase sepsis treatment at BIO-Europe

HLB Science, an affiliate of HLB Group, said Friday that it will showcase its sepsis treatment to medical experts and buyers at the BIO-Europe conference, which will be held virtually from Nov. 2 to 4. BIO-Europe is one of the largest pharmaceutical conferences in the biotechnology industry where around 2,000 companies from over 60 countries participate every year to discuss ...

Baek Byung-yeul | 2022-10-28 14:50

SK Bioscience aims to address vaccine inequality through global partnership

SK Bioscience aims to address vaccine inequality through global partnership

SK Bioscience, which developed Korea's first COVID-19 vaccine, SKYCovione, said Thursday that the biotech company aims to address the issue of vaccine inequality by intensifying collaboration with international organizations so that people living in low-income countries will be easily able to prevent life-threatening diseases. Rich, developed countries were the first to get a...

Baek Byung-yeul | 2022-10-20 16:43

HLB completes preparatory meeting with FDA for approval of liver cancer drug

HLB completes preparatory meeting with FDA for approval of liver cancer drug

Local biotech company HLB is stepping up efforts to win a novel drug approval in the United States for its liver cancer treatment Rivoceranib, after completing a pre-new drug application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company said Wednesday. The company said its U.S. subsidiary Elevar Therapeutics and China's Jiangsu Hengrui Medicine compl...

Baek Byung-yeul | 2022-10-12 17:01

Samsung chief vows to invest $5.2 bil. to create huge lead for bio business

Samsung chief vows to invest $5.2 bil. to create huge lead for bio business

Samsung Electronics Vice Chairman Lee Jae-yong has vowed to invest 7.5 trillion won ($5.2 billion) in the company's biotechnology firm by 2032 to achieve a huge lead with its competitors, Samsung Group said Tuesday. The Samsung chief attended the ceremony for the completion of Samsung Biologics' fourth drug manufacturing plant in Songdo, Incheon. The plant, which went into op...

Baek Byung-yeul | 2022-10-11 16:47

Samsung Biologics launches bispecific antibody platform S-DUAL

Samsung Biologics launches bispecific antibody platform S-DUAL

Samsung Biologics launched S-DUAL, a bispecific antibody platform developed with its own technology with an aim to improve its capability in the contract-based drug development business, the company said Thursday. Bispecific antibodies act on two factors simultaneously, not just one factor, which is more effective than a monospecific antibody that acts on only one factor.

Baek Byung-yeul | 2022-10-06 16:46

Korean biotech firms show off capabilities in Europe

Korean biotech firms show off capabilities in Europe

HLB, Celltrion, NeoImmuneTech and other Korean biotech companies confirmed their competitiveness in Europe as they showcased their new drug development capabilities at the European Society for Medical Oncology (ESMO) Congress, an annual medical oncology fair to share the latest developments in cancer research, they said Tuesday. This year's ESMO Congress was held in Paris for...

Baek Byung-yeul | 2022-09-13 16:46

HLB's liver cancer treatment shows longest overall survival

HLB's liver cancer treatment shows longest overall survival

Local biotech company HLB said its liver cancer treatment candidate Rivoceranib showed over 22 months of overall survival in its Phase 3 clinical trials, the longest in any liver cancer treatment, the company said, Thursday. The company said it plans to hold a meeting with the U.S. Food and Drug Administration (FDA) to apply for approval for new drugs, given the effectiveness...

Baek Byung-yeul | 2022-09-08 14:20

Celltrion receives approval to sell anticancer biosimilar Vegzelma in Europe

Celltrion receives approval to sell anticancer biosimilar Vegzelma in Europe

Korean biopharmaceutical firm Celltrion said Friday it has received an approval to sell its anticancer biosimilar Vegzelma in Europe.

2022-08-19 15:52

Samsung Biologics, C&T invest in US biotech firm Senda Biosciences

Samsung Biologics, C&T invest in US biotech firm Senda Biosciences

An investment fund created by Samsung Biologics and Samsung C&T invested $15 million into U.S.-based biotechnology company Senda Biosciences as part of their efforts to foster core technology required to develop next-generation biopharmaceuticals, Samsung Biologics said on Wednesday. Samsung Biologics said the Life Science Fund, jointly formed by itself and Samsung C&T, decid...

Baek Byung-yeul | 2022-08-17 16:16

1 2 3 4 5 6 7 8 9 10

Top 10 Stories

1	Scientists find green way to turn CO2 into fuel with sunlight

2	Kim Jong-un's rejection of Russia's food assistance irritates North Korean defectors

3	Opposition party in turmoil as leader could be arrested on Tuesday

4	Korea boosts subsidies to rev up falling EV sales

5	Foreign employees rewarded for contribution to Korea's shipbuilding industry

6	Russia lodges protest to S.Korean envoy over Yoon's UN speech

7	Lawmakers want to grill business tycoons over decision to rejoin FKI

8	Gov't reviews changing description of Fukushima wastewater

9	'Songpyeon' for low-income families

10	Big insurers up for sale, but financial conglomerates appear disinterested

DARKROOM